# CVS HEALTH Corp: Form 10-Q for the period ended Mar 31, 2012

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2012-05-02
- Accepted by EDGAR: May 2, 2012, 07:12 ET
- Period: 2012-03-31
- Accession: 0001104659-12-031650
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000110465912031650/a12-8646_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000110465912031650/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-01-01 to 2012-03-31 | $30.80bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2012-01-01 to 2012-03-31 | $25.68bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2012-01-01 to 2012-03-31 | $5.11bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2012-01-01 to 2012-03-31 | $1.40bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-01-01 to 2012-03-31 | $133.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-01-01 to 2012-03-31 | $496.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-01-01 to 2012-03-31 | $775.0m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2012-01-01 to 2012-03-31 | $0.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-01-01 to 2012-03-31 | $0.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-01-01 to 2012-03-31 | 1,309,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2012-01-01 to 2012-03-31 | $2.79bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2012-01-01 to 2012-03-31 | $376.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2012-01-01 to 2012-03-31 | $211.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 3 months, 2012-01-01 to 2012-03-31 | $810.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2012-03-31 | $2.21bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-03-31 | $19.89bn | us-gaap:AssetsCurrent |
| Total assets | at 2012-03-31 | $66.01bn | us-gaap:Assets |
| Current liabilities | at 2012-03-31 | $13.41bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2012-03-31 | $9.21bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2012-03-31 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2012-03-31 | $38.05bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Market risk

As filed, 284 characters.

As of March 31, 2012, the Company had no derivative financial instruments or derivative commodity instruments in place and believes its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio, is not material.

## Controls and procedures

As filed, 7,106 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of March 31, 2012, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** During the three months ended March 31, 2012, we implemented a new pharmacy cost accounting system in our Retail Pharmacy segment thereby changing our methods of accounting for prescription drug inventories in the Retail Pharmacy segment from the retail inventory method in retail pharmacies and from the FIFO cost method in distribution centers to the weighted average cost method. Other than the foregoing, there have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our 2011Annual Report on Form 10-K. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

### I. Legal Matters

1\. In August 2006, the Bellevue case and the North Jackson Pharmacy case were both transferred to Pennsylvania federal court by the Judicial Panel on Multidistrict Litigation for coordinated and consolidated proceedings with other cases before the panel, including cases against other PBMs. Caremark appealed the decision which vacated the order compelling arbitration and staying the proceedings in the Bellevue case and, following the appeal, the Court of Appeals reinstated the order compelling arbitration of the Bellevue case. Plaintiffs in the Bellevue case dismissed their lawsuit in federal court and determined not to seek arbitration and are again pursuing an appeal to the Court of Appeals of the district court ruling compelling arbitration. Motions for class certification in the coordinated cases within the multidistrict litigation, including the North Jackson Pharmacy case, remain pending, and the court has permitted certain additional class discovery and briefing. The consolidated action is now known as the In Re Pharmacy Benefit Managers Antitrust Litigation.

2\. Since March 2009, the Company has been named in a series of putative collective and class action lawsuits filed in federal courts around the country, purportedly on behalf of current and former assistant store managers working in the Company’s stores at various locations outside California. The lawsuits allege that the Company failed to pay overtime to assistant store managers as required under the Fair Labor Standards Act (“FLSA”) and under certain state statutes. The lawsuits also seek other relief, including liquidated damages, punitive damages, attorneys’ fees, costs and injunctive relief arising out of the state and federal claims for overtime pay. The Company has aggressively challenged both the merits of the lawsuits and the allegation that the cases should be certified as class or collective actions. In light of the cost and uncertainty involved in this litigation, however, the Company has reached an agreement with plaintiffs’ counsel to settle the series of lawsuits. The court granted final approval of the settlement in April 2012. The Company has established legal reserves related to these matters to fully cover the settlement payments.

3\. The Company received a subpoena from the SEC in February 2011 and has subsequently received two additional subpoenas, requesting, among other corporate records, information relating to public disclosures made by the Company during 2009, and information concerning ownership and transactions in the Company’s securities by certain officers and employees of the Company during 2009. The Company has been providing documents and other information in response to these requests for information.

### II. Environmental Matters

1\. Item 103 of SEC Regulation S-K requires disclosure of certain environmental legal proceedings if management reasonably believes that the proceedings involve potential monetary sanctions of $100,000 or more. Negotiations remain ongoing with the State of Connecticut regarding a Consent Order resolving alleged noncompliance with hazardous waste regulations by certain of the Company’s stores in Connecticut. The Company cannot predict the ultimate outcome of these negotiations; however, management does not believe that the outcome will have a material adverse effect on the Company.

2\. The Company has also received notices of violation and information requests from governmental authorities in California regarding the management of hazardous waste and certain other materials in accordance with environmental regulations. The Company cooperated fully in these matters and, like certain other large national retailers who have received similar inquiries from California governmental authorities, has reached a settlement resolving such potential claims on a statewide basis. A proposed Final Judgment negotiated by the parties was filed in the Superior Court of Ventura County, and was approved by the Court on April 16, 2012. As part of this settlement, the Company has agreed to pay $13.75 million in civil penalties, supplemental environmental projects and cost reimbursement, and has consented to injunctive provisions regarding future compliance with California waste laws.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended March 31, 2012, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2011 Repurchase Program.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| January 1, 2012 through January 31, 2012 | — | $— | — | $2,998,750,000 |
| February 1, 2012 through February 29, 2012 | 4,998,605 | $43.84 | 4,998,605 | $2,779,597,682 |
| March 1, 2012 through March 31, 2012 | 13,127,191 | $45.02 | 13,127,191 | $2,188,670,851 |
| Totals | 18,125,796 | $44.69 | 18,125,796 |  |

29

### Part II Item 6

### Exhibits

Filed May 2, 2012.
Source: SEC EDGAR, the filing index for accession 0001104659-12-031650. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
